Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Reinnervate Partners with Oncotest and SBH Sciences

Published: Thursday, October 31, 2013
Last Updated: Thursday, October 31, 2013
Bookmark and Share
Companies to partner on introductory services for screening novel anti-cancer drugs using 3D tumour cell culture.

Reinnervate Ltd today announced partnerships with two oncology-focussed CRO‟s to offer 3D tumour cell screening services. The CROs, Oncotest GmbH (Freiburg, Germany) and SBH Sciences (Natick, MA, USA) will both offer a new service for clients wishing to try out cancer 3D cell culture screening for the first time or who wish to evaluate new tumour types in their models. 

The introductory service ranges in price from $1,499 to $2,499 and has the following experimental outline: 

• Client picks two cancer cell lines from the available panel (over 200 tumour cell lines are available)
• Client provides up to 2 test compounds or specifies two commercially available drugs to be used
• CROs include one positive control cell line and one positive control compound
• All 3 compounds are tested on the specified 3D tumour cells cultured in Alvetex® 96 3D cell culture plates
• A dose response experiment with ten concentrations in duplicates will be performed using the Promega Cell Titer-Glo® assay
• CRO provides a comprehensive data report with IC50 values and a follow-up telephone conference
• Comparison of 2D and 3D tumour cell responses can be provided (depending on service chosen) 

"These new introductory 3D tumour cell services will allow more scientists to explore the differences in drug response between 2D and 3D cultured tumour cells‟ said Richard Rowling, Commercial Director at Reinnervate Ltd. "These services have been priced at a level which should be affordable for most groups that have not yet had the time to explore the improved biological relevance offered by 3D cell culture systems‟ he added. 

Torsten Giesemann, Department Head at Oncotest commented, „We have been using Alvetex® 96 3D cell culture plates for some time now and are keen to help as many clients as possible explore the potential benefits of testing new oncology drugs on 3D tumour cells cultured in a 3D format. There is an increasing body of scientific data showing that tumour cells cultured as monolayers are a poor proxy for the in vivo situation.‟ 

SBH Sciences CEO, Raphael Nir said, „We have a panel of over 200 different tumour cell lines and look forward to helping our clients evaluate 3D tumour cell screening and compare the differences in drug response between 2D and 3D cell culture systems using Alvetex® technology‟.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
New Treatment for Immune Cancers
Clinical trial shows new drug holds promise for treating advanced mastocytosis.
Sickle Cell Gene Therapy Passes Test
Researchers found a precision-engineered gene therapy virus reduced sickle-induced red-cell damage in mice with sickle cell disease.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Stem Cell Therapy Heals Injured Mouse Brain
A team of researchers has developed a therapeutic technique that dramatically increases the production of nerve cells in mice with stroke-induced brain damage.
Zika Vaccine Testing in Humans
The NAAID has initiated a clinical trail of a vaccine candidate for the prevention of the Zika virus infection.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!